Publication: Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting
6
0
Issued Date
2024-11-01
Resource Type
ISSN
20050380
eISSN
20050399
Scopus ID
2-s2.0-85208687910
Pubmed ID
38670561
Journal Title
Journal of Gynecologic Oncology
Volume
35
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Gynecologic Oncology Vol.35 No.6 (2024)
Suggested Citation
Termrungruanglert W., Khemapech N., Vasuratna A., Havanond P., Tantitamit T. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. Journal of Gynecologic Oncology Vol.35 No.6 (2024). doi:10.3802/jgo.2024.35.e85 Retrieved from: https://hdl.handle.net/20.500.14740/20934
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: To compare the health impact and economic benefits among individuals who did not receive the human papillomavirus (HPV) vaccine to those who received a single dose, or 2 doses. The comparison was stratified by 4 types of vaccine in conjunction with primary HPV screening in a low/middle-income country setting. Methods: A Markov model was employed to simulate HPV infection and cervical cancer in a cohort of 100,000 12-year-old girls free of HPV. The study scrutinized 9 strategies: 1 dose and 2 doses of 2vHPV (Cervarix®), 2vHPV (Cecolin®), 4vHPV (Gardasil®), 9vHPV vaccine (Gardasil9®), and no vaccination. The primary outcome measure was the quality-adjusted life year (QALY) of each strategy. Incremental cost-effectiveness ratios were estimated over a lifetime horizon, accompanied by sensitivity analyses conducted. Results: All vaccination programs yielded 41,298–71,057 QALYs gained accompanied by cost savings of 14,914,186–19,821,655 USD compared to no vaccination. Administering 2 doses of 9vHPV vaccine emerged as the most cost-effective strategy, boasting 406 USD/QALY, within a lower willingness to pay threshold. Sensitivity analysis demonstrated an 80% probability of the cost-effectiveness of the 2 doses of 9vHPV vaccine regimen. Furthermore, uncertainty around the costs of vaccination and vaccine efficacy exerted the most substantial influence on the cost-effectiveness findings. Conclusion: Oping for 2 doses of 9vHPV vaccine in conjunction with a primary HPV screening represents the most cost-effective option for implementing a school-based HPV vaccination program targeting 12-year-old girls in Thailand. Such findings provide valuable insights for policymakers in the realm of cervical cancer prevention.